Back to News
Market Impact: 0.3
AbbVie's QULIPTA Outperforms Topiramate In Phase 3 Migraine Prevention Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
AbbVie reported that QULIPTA (atogepant) showed better tolerability and efficacy than Topiramate in the Phase 3 TEMPLE study. Fewer patients discontinued treatment because of side effects, and more achieved a substantial reduction in the study’s measured outcome; the provided article text does not specify the outcome or numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
ABBV0.75
More News
- West Reports Third-Quarter 2026 Results
- Piramal Pharma Limited annonce ses résultats pour le deuxième trimestre et le premier semestre de l'exercice 2027
- We’re downgrading Alphabet after its rough quarter. Here’s where we’d buy again
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks